Profile data is unavailable for this security.
About the company
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
- Revenue in USD (TTM)5.95k
- Net income in USD-42.24m
- Incorporated2017
- Employees26.00
- LocationAditxt Inc737 N. Fifth Street, Suite 200RICHMOND 23219United StatesUSA
- Phone+1 (909) 488-0844
- Fax+1 (302) 674-2100
- Websitehttps://aditxt.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Helix BioMedix Inc | 2.07m | -2.58m | 609.46k | 8.00 | -- | 0.3887 | -- | 0.295 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
| Bio Path Holdings Inc | 0.00 | -11.18m | 635.86k | 10.00 | -- | -- | -- | -- | -1.71 | -1.71 | 0.00 | -0.866 | 0.00 | -- | -- | 0.00 | -611.66 | -81.00 | -- | -90.58 | -- | -- | -- | -- | -- | -65.76 | -- | -- | -- | -- | 38.46 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 389.79k | -5.33m | 716.69k | 5.00 | -- | 0.4818 | -- | 1.84 | -2.41 | -2.41 | 0.1286 | 0.3219 | 0.1729 | -- | 25.08 | 77,958.00 | -236.36 | -101.93 | -336.65 | -125.09 | -- | -- | -1,367.34 | -592.18 | -- | -- | 0.00 | -- | 19.29 | -5.04 | -8.60 | -- | -- | -- |
| Avenue Therapeutics Inc | 1.40m | -3.74m | 783.12k | 2.00 | -- | 0.2202 | -- | 0.5578 | -1.55 | -1.55 | 0.50 | 1.12 | 0.4422 | -- | -- | 702,000.00 | -119.06 | -159.81 | -122.59 | -215.40 | -- | -- | -269.23 | -- | -- | -- | 0.00 | -- | -- | -- | -12.29 | -- | -- | -- |
| THC Farmaceuticals Inc | 7.58k | -60.45k | 797.79k | 2.00 | -- | 0.3118 | -- | 105.25 | -0.0036 | -0.0036 | 0.0005 | 0.1411 | -- | -- | -- | 3,790.00 | -- | -- | -- | -- | 100.00 | -- | -1,591.69 | -- | -- | -- | 0.2051 | -- | 348.43 | -- | 5,170.19 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -49.19m | 810.34k | 8.00 | -- | -- | -- | -- | -175.56 | -175.56 | 0.00 | -3.04 | 0.00 | -- | -- | 0.00 | -282.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -52.12 | -- | -- | -- |
| Aditxt Inc | 5.95k | -42.24m | 853.38k | 26.00 | -- | -- | -- | 143.43 | -13,234.74 | -13,234.74 | 0.3444 | -151.86 | 0.0003 | 1.54 | 0.0304 | 228.85 | -207.03 | -148.78 | -- | -279.11 | -1,134.96 | -- | -724,419.70 | -8,283.15 | 0.02 | -12.48 | -- | -- | -79.23 | -- | -23.40 | -- | -- | -- |
| Protagenic Therapeutics Inc | -100.00bn | -100.00bn | 872.05k | 1.00 | -- | -- | -- | -- | -- | -- | -- | -2.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2945 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Emmaus Life Sciences Inc | 11.89m | -7.29m | 894.12k | 34.00 | -- | -- | -- | 0.0752 | -0.1141 | -0.1141 | 0.1862 | -0.9315 | 0.4945 | 0.6596 | 3.13 | 349,794.10 | -30.31 | -14.68 | -- | -211.99 | 92.17 | 90.14 | -61.29 | -32.65 | 0.0557 | -0.1912 | -- | -- | -43.73 | -6.05 | -72.86 | -- | -27.52 | -- |
| CeCors Inc | -100.00bn | -100.00bn | 996.24k | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| International Stem Cell Corp | 9.39m | -149.00k | 1.08m | 32.00 | -- | -- | 6.72 | 0.1152 | -0.0187 | -0.0187 | 1.17 | 0.0655 | 1.80 | 2.66 | 11.08 | 293,468.80 | -1.13 | -16.11 | -10.84 | -52.88 | 57.86 | 59.53 | -0.6283 | -10.91 | 0.4604 | 0.6258 | 0.8632 | -- | 16.64 | -0.8308 | -59.54 | -- | -19.12 | -- |
| Herborium Group Inc | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 1.13m | 3.00 | 0.6897 | -- | 44.61 | 4.02 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| G1 Execution Services LLCas of 31 Dec 2025 | 16.08k | 2.87% |
| HRT Financial LPas of 31 Dec 2025 | 15.90k | 2.84% |
| Jane Street Capital LLCas of 31 Dec 2025 | 12.84k | 2.30% |
| Flow Traders U.S. LLCas of 31 Dec 2025 | 12.45k | 2.23% |
| Tower Research Capital LLCas of 31 Dec 2025 | 937.00 | 0.17% |
| UBS Securities LLCas of 31 Dec 2025 | 620.00 | 0.11% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 5.00 | 0.00% |
| Danske Bank A/S (Investment Management)as of 31 Dec 2025 | 2.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2025 | 2.00 | 0.00% |
| IFP Advisors LLCas of 31 Dec 2025 | 2.00 | 0.00% |
